Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Corcept Mifepristone Phase III Trials For Depression Underway – IPO

Executive Summary

Corcept Therapeutics expects to complete analysis of Phase III data on mifepristone for psychotic major depression by the end of 2003

You may also be interested in...



Corcept To Test Sluggish IPO Market For Biotechs

Corcept Therapeutics will test the sluggish market for biopharmaceutical initial public offerings with an IPO slated for June 10

Corcept To Test Sluggish IPO Market For Biotechs

Corcept Therapeutics will test the sluggish market for biopharmaceutical initial public offerings with an IPO slated for June 10

Mifeprex Label Allows Use By Physicians Not Trained In Surgical Abortion

The Population Council and Danco Labs will conduct a postmarketing safety study to compare outcomes for Mifeprex (mifepristone) patients treated by physicians trained in surgical abortion versus those treated by physicians not trained in abortion.

UsernamePublicRestriction

Register

PS039085

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel